PD15-06 TIMING OF ADJUVANT CHEMOTHERAPY AND SURVIVAL FOLLOWING RADICAL CYSTECTOMY

Abstract

You have accessJournal of UrologyBladder Cancer: Invasive II1 Apr 2018PD15-06 TIMING OF ADJUVANT CHEMOTHERAPY AND SURVIVAL FOLLOWING RADICAL CYSTECTOMY Joshua Jue, Zachary Kroeger, Tulay Koru-Sengul, Feng Miao, Kevin Moore, Mahmoud Alameddine, Chad Ritch, and Mark Gonzalgo Joshua JueJoshua Jue More articles by this author , Zachary KroegerZachary Kroeger More articles by this author , Tulay Koru-SengulTulay Koru-Sengul More articles by this author , Feng MiaoFeng Miao More articles by this author , Kevin MooreKevin Moore More articles by this author , Mahmoud AlameddineMahmoud Alameddine More articles by this author , Chad RitchChad Ritch More articles by this author , and Mark GonzalgoMark Gonzalgo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.805AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Radical cystectomy (RC) is the standard of care for surgical management of patients with muscle-invasive bladder cancer (MIBC). The use of perioperative chemotherapy is also important for achieving optimal outcomes. We investigated the impact of timing of adjuvant chemotherapy (AC) on survival following radical cystectomy. METHODS Patients with newly diagnosed pT2-T4, N0, M0 urothelial cell carcinoma who received no chemotherapy prior to RC were identified in the National Cancer Data Base (NCDB). Patients who underwent RC and received no AC or patients who received AC > 45 days following RC were propensity matched to patients receiving AC = 45 days following RC. Median survival was calculated using Kaplan-Meier analysis. Adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) were calculated from a multivariable Cox regression model to examine factors affecting overall survival (OS). RESULTS A total of 284 patients with MIBC treated with AC within 45 days of RC were identified from 2004-2014. Patients who received AC = 45 days following RC had better 5 year OS (47.0%, 95% CI: 40.6%-53.2%) compared to patients who received AC > 45 days following RC (37.5%, 95% CI: 31.4%-43.7%) or no AC (41.2%, 95% CI: 35.0%-47.2%). There was no significant difference in OS between patients who received AC > 45 days and no AC (1.11, 0.89-1.38, p=0.348). AC > 45 days and no AC were significant predictors of worse OS compared to AC = 45 days (1.27, 1.02-1.59, p=0.033 and 1.41, 1.12-1.78, p=0.003). CONCLUSIONS Patients who received AC = 45 days following RC had better overall survival compared to patients who received AC > 45 days or no AC following RC. These data highlight the importance of appropriate timing of AC following RC. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e312 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Joshua Jue More articles by this author Zachary Kroeger More articles by this author Tulay Koru-Sengul More articles by this author Feng Miao More articles by this author Kevin Moore More articles by this author Mahmoud Alameddine More articles by this author Chad Ritch More articles by this author Mark Gonzalgo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...